Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.
5 affiliations
- 1Knownwell, San Diego, CA, USA.
- 2Louisville Metabolic and Atherosclerosis Research Center, Monroe Biomedical Research, Louisville, KY, USA.
- 3University College Dublin, Belfield, Dublin, Ireland.
- 4Ulster University, Coleraine, UK.
- 5Eli Lilly and Company, Indianapolis, IN, USA.
Abstract
In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT), EQ-5D-5L and associated EQ visual analog scale (EQ VAS), and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) for Physical Activity. Post-hoc analysis assessed changes in outcomes among orforglipron-treated participants by body mass index (BMI) subgroups (<35 kg/m2, ≥35 to <40 kg/m2, and ≥40 kg/m2) and by baseline physical function limitations, as defined by PGIS. A mixed-model for repeated-measures (MMRM) was used, adjusting for treatment and key covariates. Across both ATTAIN trials, participants receiving orforglipron demonstrated greater improvements than those on placebo in PROs across most SF-36v2, IWQOL-Lite-CT and EQ-5D-5L domain scores from baseline through week 72. Significant improvements were observed across PROs related to physical function. In the exploratory subgroup analyses, participants in ATTAIN-1 with higher baseline BMI and those with baseline physical function limitations were more likely to have greater improvements. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620.
Related
- Reported cardiovascular events and cardiometabolic risk markers with orforglipron and danuglipron in adults with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized trials
- A scoping review of psychosocial functioning in young people with personality pathology: current evidence and methodological issues
- Psychosomatic symptom burden and family functioning of adolescents with chronic diseases in transition to adult medicine – Implications for psychosocial support
- Psychosocial functioning of patients after left ventricular assist device implantation as destination therapy for heart failure
- The longitudinal relationship between physical capacity and self-perceived physical functioning after total hip and knee arthroplasty
BibTeX
@article{look2026orforglipron,
title = {{Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.}},
author = {Michelle Look and Harold Bays and Carel W Le Roux and Neena A Xavier and Sheryl Elaine Allen and Irina Jouravskaya and Adam Stefanski and Georgios K Dimitriadis and Benjamin Behrend and Wenyu Ye and Jinhong Li and Theresa Hunter Gibble and Christy Houle},
journal = {Obesity pillars},
year = {2026},
month = oct,
doi = {10.1016/j.obpill.2026.100347},
url = {https://europepmc.org/article/MED/42999545},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.
AU - Michelle Look
AU - Harold Bays
AU - Carel W Le Roux
AU - Neena A Xavier
AU - Sheryl Elaine Allen
AU - Irina Jouravskaya
AU - Adam Stefanski
AU - Georgios K Dimitriadis
AU - Benjamin Behrend
AU - Wenyu Ye
AU - Jinhong Li
AU - Theresa Hunter Gibble
AU - Christy Houle
PY - 2026
DA - 2026/10/13
JO - Obesity pillars
DO - 10.1016/j.obpill.2026.100347
UR - https://europepmc.org/article/MED/42999545
AB - In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. This was a prespecified secondary and post-hoc analyses of patient-reported outcomes (PRO) (ATTAIN-1 and ATTAIN-2). Health-Related Quality of Life (HRQoL) was assessed from baseline to week 72 (efficacy estimand) using Short Form-36 Version 2 Health Survey acute form (SF-36v2), Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT), EQ-5D-5L and associated EQ visual analog scale (EQ VAS), and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) for Physical Activity. Post-hoc analysis assessed changes in outcomes among orforglipron-treated participants by body mass index (BMI) subgroups (<35 kg/m2, ≥35 to <40 kg/m2, and ≥40 kg/m2) and by baseline physical function limitations, as defined by PGIS. A mixed-model for repeated-measures (MMRM) was used, adjusting for treatment and key covariates. Across both ATTAIN trials, participants receiving orforglipron demonstrated greater improvements than those on placebo in PROs across most SF-36v2, IWQOL-Lite-CT and EQ-5D-5L domain scores from baseline through week 72. Significant improvements were observed across PROs related to physical function. In the exploratory subgroup analyses, participants in ATTAIN-1 with higher baseline BMI and those with baseline physical function limitations were more likely to have greater improvements. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620.
SN - 2667-3681
ER -